Supplemental Tables 1 and 2 and Figures 1-3 from The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

Supplemental Tables 1 and 2 and Figures 1-3. Supplemental Table 1: Cell line resistance mechanisms Supplemental Table 2: Ic50 values for BI-847325 on the cell line panel Supplemental Figure 1: BI-847325 blocks the proliferation and induces apoptosis in BRAF-mutant melanoma Supplemental Figure 2: MEK and Aurora kinase inhibitors do not decrease expression of Mcl-1 and MEK. Supplemental Figure 3: Inhibition of the proteasome does not reverse the effects of BI-847325 upon MEK expression.